Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464383 · ClinicalTrials.gov registry record · Phase 4
Anxiety and Depression in Epilepsy: A Treatment Study
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
NCT03464383 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 69 participants.
The verdict
NCT03464383, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
Study Summary
As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this randomized trial aims to study treatment for anxiety and depression in epilepsy taking place directly within the epilepsy clinic vs. psychiatry referral (typical care). Patients that meet eligibility criteria, including significant symptoms of depression and/or anxiety, will be randomized to the either the intervention group or the control group. Patients that do not meet eligibility requirement or decline the study intervention will have the option of participating in the survey arm of the study. The intervention will consist of an initial prescription for an FDA-approved medication to treat depression/anxiety and telephone-based chronic care management plan for repeated symptom measurement and side effect surveillance. The control group will receive usual care, which is a referral order to psychiatry placed by their treating neurologist. Participants in the survey arm of the study will complete a one time survey.
Interventions
- DRUG Escitalopram 10mg
- OTHER Referral to Psychiatry
- OTHER Survey only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464383
The ClinicalTrials.gov registry entry for NCT03464383 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Escitalopram 10mg is the first listed.
NCT03464383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03464383 about?
NCT03464383 is a clinical study titled "Anxiety and Depression in Epilepsy: A Treatment Study". As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this randomized trial aims to study treatment for anxiety and depression in epilepsy taking place directly within the epilepsy clinic vs. psychiatry referral (typical...
What is the current status of trial NCT03464383?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2018-05-07. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT03464383?
The interventions under investigation include: Escitalopram 10mg (DRUG), Referral to Psychiatry (OTHER), Survey only (OTHER).
Who is sponsoring clinical trial NCT03464383?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.